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Abstract
Aims/hypothesis The innate immune cells, invariant natural
killer T cells (iNKT cells), are implicated in the pathogenesis
of psoriasis, an inflammatory condition associated with
obesity and other metabolic diseases, such as diabetes and
dyslipidaemia. We observed an improvement in psoriasis
severity in a patient within days of starting treatment with an
incretin-mimetic, glucagon-like peptide-1 (GLP-1) receptor
agonist.Thiswasindependentofchangeinglycaemiccontrol.
We proposed that this unexpected clinical outcome resulted
from a direct effect of GLP-1 on iNKTcells.
Methods We measured circulating and psoriatic plaque
iNKT cell numbers in two patients with type 2 diabetes
and psoriasis before and after commencing GLP-1 analogue
therapy. In addition, we investigated the in vitro effects of
GLP-1 on iNKT cells and looked for a functional GLP-1
receptor on these cells.
Results The Psoriasis Area and Severity Index improved in
both patients following 6 weeks of GLP-1 analogue
therapy. This was associated with an alteration in iNKT
cell number, with an increased number in the circulation
and a decreased number in psoriatic plaques. The GLP-1
receptor was expressed on iNKT cells, and GLP-1 induced
a dose-dependent inhibition of iNKT cell cytokine secre-
tion, but not cytolytic degranulation in vitro.
Conclusions/interpretation The clinical effect observed and
the direct interaction between GLP-1 and the immune
system raise the possibility of therapeutic applications for
GLP-1 in inflammatory conditions such as psoriasis.
Keywords Anti-inflammatory.CREB.Diabetes.GLP-1
analogue.GLP-1 receptor.Innate immune system.
Invariant NKT cells.Obesity.Psoriasis
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Introduction
Psoriasis is an immune-mediated disease associated with
obesity and other metabolic disorders, such as diabetes and
dyslipidaemia [1–4]. Patients with psoriasis are more likely
to be obese than non-psoriatic controls. Obesity is more
prevalent in patients with severe rather than mild psoriasis
[1]. Both conditions are associated with chronic systemic
inflammatory activation [5, 6] and an increased risk of
cardiovascular morbidity and mortality [7–9].
We have previously reported that obesity is associated
with innate immune cell dysfunction, a key feature of
psoriasis [10, 11]. We have demonstrated that, compared
with lean individuals, obese individuals have decreased
circulating natural killer cell number and function [10], and
also have lower invariant natural killer T cell (iNKT cell)
accumulation in the omentum [11]. iNKT cells are a rare
subset of innate T cells that exert multiple immunoregula-
tory functions. They recognise glycolipid antigens, such as
the marine sponge-derived glycolipid α-galactosylceramide
(α-GalCer), presented on the MHC-like molecule, CD1d.
Upon stimulation, iNKT cells can rapidly produce multiple
cytokines that direct the immune response towards a pro-
inflammatory (Th1 or Th17) or an anti-inflammatory (Th2)
bias [12]. iNKT cells are implicated in the pathogenesis of
various obesity-related diseases, including psoriasis [13],
cancer [14, 15] and arthritis [16, 17].
The incretin pathway is a therapeutic target for obesity
and diabetes [18]. The incretin effect results from release of
hormones such as glucagon-like peptide-1 (GLP-1) from
intestinal cells in response to glucose ingestion, enhancing
insulin release and reducing postprandial excursions of
plasma glucose. Long-acting GLP-1 analogues, GLP-1
receptor agonists and inhibitors of GLP-1 enzymatic
degradation are increasingly used in type 2 diabetes to
improve glycaemic control and enhance weight loss. The
GLP-1 receptor (GLP-1R) is widely distributed in pancre-
atic islets, brain, heart, kidney and the gastrointestinal tract
[19]. GLP-1R has also been demonstrated in murine
immune tissues [20], and on T and B lymphocytes from
mice [20, 21] and humans [22]. Several reports indicate a
role for the incretin hormones in regulation and migration
of murine [20, 21, 23] and human [22] T lymphocytes. The
effects of incretin hormones on human iNKT cell function
have not yet been described.
In the present study, we observed an unexpected
beneficial effect on co-existing psoriasis in an obese, type 2
diabetes patient on GLP-1 therapy. The improvement in
psoriasis symptoms began within days, and prior to weight
loss or significant improvements in glycaemic control. We
hypothesised that GLP-1 may influence psoriasis severity by
interacting directly with the innate immune system, in
particular iNKTcells.
Methods
Index patient The index patient was a 60-year-old woman
with type 2 diabetes and BMI 37 kg/m
2. She had had
extensive, refractory psoriasis since childhood, requiring
several inpatient admissions and multiple treatments with
systemic agents. Prior to treatment she had a Psoriasis Area
and Severity Index (PASI) greater than 15. She complained
of extensive, itchy psoriasis causing marked sleep disrup-
tion. A GLP-1R agonist, exenatide, was initiated for
treatment of type 2 diabetes. Within 2 days she reported
an improvement in psoriasis severity, with decreased itch
and less sleep disruption. By 2 weeks the PASI was 10.5.
This patient experienced nausea in association with exena-
tide, requiring discontinuation after 2 months of treatment.
The psoriasis symptoms quickly began to recur, with PASI
reaching 15.3 by the end of 2 weeks. The patient then
commenced a trial of liraglutide, a GLP-1 analogue, and
reported prompt improvement in itch and thinning of
psoriatic plaques. By the end of 3 weeks the PASI had
fallen to 10.2. After 9 months of liraglutide therapy
psoriasis symptoms remain stable (PASI 10.5).
Other participants Following the observed improvement in
psoriasis in the index patient, we started two additional
obese participants with psoriasis and well-controlled type 2
diabetes on liraglutide. St Vincent’s University Hospital
Medical Research Ethics Committee approved this study, and
written informed consent was obtained from each participant
prior to the start of any research activities. We characterised
the circulatory and plaque levels of iNKTcells at baseline and
following 6 weeks of GLP-1 analogue therapy in these two
participants. The clinical improvement in the index patient
was unexpected so we were unable to study the immunolo-
gical profile before and after treatment in this case.
Enumeration of iNKT cells by flow cytometry Peripheral
blood mononuclear cells (PBMCs) were isolated from
patients by density gradient centrifugation (300 g) over
Lymphoprep (Nycomed, Oslo, Norway). Skin biopsies were
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(wt/vol.) collagenase type 1A (Sigma-Aldrich, Wicklow,
Ireland) to obtain single-cell suspensions. iNKT cells were
enumerated by staining with a pairing of phycoerythrin-
conjugated anti-iNKT cell monoclonal antibody (mAb)
(clone 6B11) and phycoerythrin-Cy5-conjugated anti-CD3
mAb, or with FITC-conjugated anti-Vα24 T cell receptor
(TCR) mAb and a phycoerythrin-conjugated anti-Vβ11
mAb. Cells were acquired using a flow cytometer (FACS
Caliber, BD Biosciences, NJ, USA) and analysed using Cell
Quest Pro (BD Biosciences) using Flow Minus One
controls. iNKT cell numbers are expressed as a percentage
of lymphocytes or T cells.
Generation of iNKT cell lines PBMCs were isolated from
healthy blood donors as previously described. iNKT cells
were isolated from PBMCs by magnetic bead separation
with an anti-iNKT cell bead (Miltenyi Biotec, Bergisch-
Gladbach, Germany). iNKT cells were further enriched by
flow cytometric sorting of 6B11-positive cells using a cell
sorter (FACS Aria; BD Biosciences). Sorted iNKT cells
were expanded in vitro by culturing 1,000 iNKT cells in
complete RPMI medium and stimulating them with 1 μg/ml
phytohaemagglutinin (Sigma-Aldrich) and 250 U/ml IL-2
(R&D Systems, Oxford, UK) in the presence of an excess
(2×10
5) of irradiated allogeneic PBMCs prepared from two
donors. After 24 and 48 h, cell culture medium was
replaced with medium containing 250 U/ml IL-2. Cell lines
were expanded for 2 to 4 weeks in the presence of IL-2
medium. Purity and phenotype of iNKT cell lines were
assessed by flow cytometry after staining the cells with
mAbs specific for CD3, 6B11, Vα24, Vβ11, CD4 and
CD8.
Glycolipidpreparation α-GalCer (Funakoshi, Tokyo, Japan)
stocks were prepared by suspending solid α-GalCer in
DMSO to a final concentration of 1 mg/ml by heating for
2 min at 80°C, followed by sonication for 5 min and
vortexing for 1 min. These stocks were stored at −20°C.
Analysis of cytokine secretion by iNKT cells iNKT cells
were stimulated in vitro using CD1d-transfected C1R cells
pulsed with glycolipid. For the cytokine production assay, 2×
10
5 C1R-transfected cells were cultured in round-bottomed
96-well tissue culture plates and pulsed with 100 ng/ml
glycolipid antigen for 1 h before adding an equal number of
iNKTcells, with or without GLP-1 (1–150 μg) or the GLP-1
analogue liraglutide (15 μg/ml). Phorbol myristate acetate
(PMA) (10 ng/ml) and ionomycin (1 μg/ml) were used as a
positive control, and iNKT cells in the absence of C1R cells
and αGalCer as a negative control. Pre-treatment with
10 μg/ml exendin 9-39 was used in blocking experiments
prior to stimulation and GLP-1 treatment. After 24 h,
supernatant fraction concentrations of IFN-γ and IL-4 were
determined by ELISA.
Analysis of cytolytic degranulation of iNKT cells iNKT
cells, treated with or without the GLP-1 analogue (15 μg/ml),
were co-cultured with CD1d
+ HeLa cells and Jurkat target
cells. Cells were examined by flow cytometric analysis for
CD107a expression on 6B11-positive effector iNKT cells. In
these experiments, iNKT cells and target cells were co-
cultured for 4 h in the presence of anti-CD107a mAb and
monensin (25 μmol/l; Sigma-Aldrich). Monensin was used
to prevent re-internalisation of CD107a.
Detection and quantification of GLP1R mRNA RNA was
extracted from previously described iNKT cell lines using
a total RNA isolation kit as per the manufacturer’s
instructions (Macherey-Nagel; Thermo Fisher Scientific,
Loughborough, UK). A cell concentration of 1.5×10
6
was used. The RNA was quantified using the nano-drop
system and qualitatively assessed using a bioanalyser
(Agilent Biosystems, Cork, Ireland). The integrity of the
RNA was determined by the RNA integrity number (RIN).
A starting concentration of 1 μg RNA was used for cDNA
synthesis using a cDNA synthesis kit (Omniscript; Qiagen,
Crawley, UK) including a negative control. The 50 μlP C R
reaction mix was made up using a kit (GoTaq Flexi kit;
Promega, Madison, WI, USA), with 10 μl reaction buffer,
1 mmol/l MgCl2, 0.2 mm dNTPs, 0.2 μmol/l forward and
reverse primers, and 1.25 U Taq polymerase using a 1:10
dilution of stock cDNA as the PCR template. GLP1R
expression analysis was quantified using the reference
gene β-actin. The optimal PCR conditions for GLP1R and
β-actin were: 95°C for 3 min; 35 cycles at 95°C for 30 s,
57°C for 30 s and 72°C for 30 s; and then 72°C for 7 min.
No template and negative controls containing water-based
cDNA were used to rule out component contamination.
Results were visualised by means of 1% agarose gels and
using the AutoChemi System (UVP BioImaging Systems,
Cambridge, UK). Real-time PCR was performed using
Qiagen QuantiTect primers for GLP1R and β-actin in
cultured iNKT cell lines and in HEK 293, which are
negative for GLP1R. The master mix was comprised of
12.5 μl SYBR Green (Promega), 1 μl of a 1:10 dilution of
stock cDNA as the PCR template and 2.5 μlo fp r i m e r
assay. No template controls were used to eliminate reagent
contamination. The RT-PCR conditions were 95°C for
10 min and 40 cycles of 94°C for 15 s, 55°C for 30 s and
72°C for 30 s.
Primers for GLP1R were: forward 5-TCAAGGTCA
ACGGCTTATTAG-3, reverse 5-TAACGTGTCCCTAGAT
GAACC-3. Primers for β-actin were: forward 5-CACCTT
CACCGTTCCAGTT-3, reverse 5-CTCTTCCAGCCAGCC
TTCCTTCCT-3.
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cytometry iNKT cells (2×10
5) were surface-stained with
the iNKT cell TCR mAb anti-6B11 (FITC), anti-CD4 and
anti-CD3 (APC). Cells were fixed using 4% paraformalde-
hyde [wt/vol.], permeabilised using 0.2% saponin and then
incubated with the anti-GLP-1R mAb (phycoerythrin) or
relevant isotype control. Cells then underwent flow cytom-
etry and results were analysed using FlowJo software
(Treestar, Ashland, OR, USA).
cAMP assay iNKT cells (1.5×10
6) were seeded in the
presence or absence of plate-bound anti-CD3 (2 μg/ml) and
culturedwiththeGLP-1analogue(15μg/ml)fortheindicated
times. As a positive control, cells were incubated for 15 min
with the cAMP phosphodiesterase inhibitor, 3-isobutyl-1-
methylxanthine (500 μmol/l), and then stimulated for another
30 min with forskolin (30 μmol/l). Cells were washed twice
with ice-cold PBS (1 ml), lysed in lysis buffer (250 μl) and
subjected to two freeze–thaw cycles. Lysates were assessed
for levels of intracellular cAMP using a cAMP assessment kit
as per the manufacturer's instructions (R&D Systems).
Measurement of cAMP response element-binding protein
phosphorylation iNKT cells (2×10
6) were seeded in the
presence or absence of plate-bound anti-CD3 (2 μg/ml) and
cultured with the GLP-1 analogue (15 μg/ml) or lipopoly-
saccharide (100 ng/ml) for the indicated times. Cells were
washed in ice-cold PBS (1 ml) and lysed in RIPA lysis
buffer (50 μl) (50 mmol/l Tris–HCl, pH 7.5, containing
150 mmol/l NaCl, 1% [wt/vol.] IGEPAL, 1% [wt/vol.]
sodium deoxycholate, 1 mmol/l Na3VO4, 1 mmol/l dithio-
threitol, 1 mmol/l phenylmethylsulfonyl fluoride and
protease inhibitor mixture consisting of leupeptin [25 μg/
ml], aprotinin [25 μg/ml], benzamidine [1 mmol/l] and
trypsin inhibitor [10 μg/ml]). Cell lysates were centrifuged
at 12,000 g for 10 min. The supernatant fractions were
mixed with 4× sample loading buffer (0.125 mol/l Tris–
HCl, pH 6.8, containing 20% [wt/vol.] glycerol, 4% [wt/
vol.] SDS, 1.4 mol/l 2-mercaptoethanol and 0.0025% [wt/
vol.] Bromophenol Blue). Samples were then resolved by
SDS-PAGE, transferred to nitrocellulose membrane and
probed for immunoreactivity using anti-phospho-cAMP
response element-binding protein (CREB) (Santa Cruz,
Heidelberg, Germany), anti-CREB (Santa Cruz) and anti-
β-actin (Sigma-Aldrich) specific antibodies. Immunoreac-
tive bands were detected using an infrared imaging system
(Odyssey; LI-COR Biosciences, Lincoln, NE, USA)
according to the manufacturer’s instructions.
Statistical analysis All statistical analyses were performed
with Prism version 5.0b software (GraphPad Software, San
Diego, CA, USA). Data are presented as mean ± SEM.
Groups were compared using Student’s t test or Mann–
Whitney U test as appropriate. p values of p<0.05 were
considered statistically significant.
Results
GLP-1analoguetherapyimprovespsoriasisandisassociated
witharedistributionofiNKTcellsbetweenthecirculationand
psoriatic plaques Psoriasis improved in both participants
Table 1 Clinical profile and iNKT cell data from non-index
participants 1 and 2 at baseline and 6 weeks following commencement
of GLP-1 analogue treatment
Variable Participant 1 Participant 2
Age (years) 48 49
Sex Male Male
Diabetes duration (years) 2 4
Co-morbidities
Hypertension Yes Yes
Dyslipidaemia No Yes
Osteoarthritis Yes No
Relevant medications
Metformin Yes Yes
Aspirin Yes Yes
Diuretic Yes No
Calcium channel blocker Yes Yes
ACE inhibitor No Yes
Statin No Yes
Psoriasis treatment
a No No
Body weight (kg)
Baseline 159.1 137.8
6 weeks 154.0 131.6
BMI (kg/m
2)
Baseline 48.0 43.0
6 weeks 46.5 41.1
HbA1c, % (mmol/mol)
Baseline 5.7 (38) 5.9 (40)
6 weeks 5.6 (37) 5.8 (39)
PASI
Baseline 13.2 4.8
6 weeks 10.8 3.8
iNKT cells (% of lymphocytes)
Skin
Baseline 2.16 0.32
6 weeks 0.07 0.00
Blood
Baseline 0.15 0.16
6 weeks 0.6 0.57
aTopical or oral treatment within previous 6 months
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improved from 13.2 to 10.8 in participant 1 and from 4.8 to
3.8 in participant 2. iNKT cell number increased in the
circulation following 6 weeks of therapy. This was
accompanied by a decrease in iNKT cell number in
psoriatic plaques (Table 1).
iNKT cells express GLP1R and signal in response to
GLP-1 Given the capacity of the GLP-1 agonist to promote
such clear re-distribution of iNKT cells from the skin into
the circulation, we next assessed the ability of GLP-1 to act
directly on iNKT cells. This was addressed by initially
probing for GLP1R expression in these cells and investi-
gating the ability of GLP-1 to trigger downstream intracel-
lular signalling pathways. We examined polyclonal iNKT
cell lines for human GLP1R by conventional PCR and real-
time PCR. All lines were found to express GLP1R mRNA
(Fig. 1a, b). To further complement this finding, intracel-
lular flow cytometry was employed to confirm that GLP-1R
is also produced at the protein level in iNKT cells (Fig. 1c).
We next assessed the ability of GLP-1R-producing iNKT
cells to signal in response to GLP-1. Given that GLP-1R is
a G-protein-coupled receptor that couples to the stimulatory
Gs protein and activates adenylate cyclase and hence cAMP
production, we examined the ability of GLP-1 to regulate
levels of cAMP in iNKT cells. Stimulation of GLP-1R by
the GLP-1 analogue resulted in a time-dependent upregu-
lation of levels of cAMP (Fig. 2a). While levels of cAMP
were somewhat reduced in CD3-activated iNKT cells,
stimulation of GLP-1R in these latter cells also showed
time-dependent increases in levels of cAMP. Given that
cAMP can activate the downstream enzyme protein kinase A,
which in turn phosphorylates the transcription factor
CREB, we were keen to show that the GLP-1R could
also trigger these downstream signalling components.
Stimulation of GLP-1R induced a time-dependent phos-
phorlyation of the transcription factor CREB and was
further augmented when iNKT cells were activated with
CD3 (Fig. 2b). There was no change in total levels of
CREB or the housekeeping protein β-actin. These findings
confirm that iNKT cells produce a functional GLP-1R,
w h i c hc a nr e s p o n dt oG L P - 1a n dt r i g g e rd o w n s t r e a m
signal transduction cascades.
GLP-1 modulates iNKT cell cytokine production in a GLP-
1R-dependent manner We next investigated the effects of
GLP-1 on the function of iNKT cells. Native GLP-1
increased cytokine production by approximately two fold
in resting iNKT cells (IFN-γ p<0.0001, IL-4 p<0.005;
Fig. 3a, b). This occurred independently of αGalCer.
Fig. 1 iNKT cells express
GLP-1R. a Expression of
GLP1R mRNA by iNKT cell
lines as determined by RT-PCR.
Values were normalised to levels
of β-actin (n=4). b Quantifica-
tion of expression of GLP1R by
iNKT cells measured by real-
time PCR; expression was also
measured on a GLP-1R-negative
HEK-293 cell line as a negative
control; n=3;
†p<0.0001. c
Flow cytometry dot plots show-
ing representative HEK-293 cell
line, CD3
+ T cell line and iNKT
cell line stained with the mAb
GLP-1R phycoerythrin (PE) and
mAbs for either CD3 APC
(Tcells) or iNKTcell TCR FITC
(iNKT cells). FMO, Flow Minus
One control for each cell line.
Gates were determined by FMO
and unstained samples (not
shown) (n=5)
Diabetologia (2011) 54:2745–2754 2749However, GLP-1 showed dose-dependent inhibitory effects
on the ability of αGalCer-loaded CD1d-transfected C1R
cells to induce IFN-γ and IL-4 production in iNKT cells
(Fig. 3c, d). As the GLP-1R antagonist exendin 9-39
abrogated the capacity of GLP-1 to modulate iNKT cell
cytokine production, the above inhibitory effects of GLP-1
on stimulated iNKT cells must be mediated via GLP-1R
(Fig. 4a, b). To determine whether GLP-1 modulation was
due to interference in the interaction between CD1d/
αGalCer and the T cell receptor complex, we stimulated
iNKT cells with PMA/ionomycin in the absence and
presence of GLP-1. We observed a significant reduction in
cytokine (IFN-γ and IL-4) upon the addition of GLP-1 to
stimulated iNKT cell cultures (Fig. 4c, d), indicating that
GLP-1 does not directly target the CD1d/TCR complex
interaction.
The GLP-1 analogue liraglutide modulates iNKT cell
cytokine production, but not cytolytic degranulation GLP-
1 has a very short half-life in vivo and thus longer-acting
analogues, such as liraglutide, are used in the clinical
setting. We investigated whether liraglutide could mimic the
regulatory effects of endogenous GLP-1 on iNKT cells. As
seen with native GLP-1, the GLP-1 analogue significantly
decreased production of IFN-γ and IL-4 (p<0.0001;
Fig. 5a). Finally, we investigated whether the GLP-1
analogue modulated the cytolytic degranulation of stimu-
lated iNKT cells, but observed no effect on mobilisation of
CD107
+ cytolytic granules (Fig. 5c).
Discussion
We have observed an improvement in psoriasis following
GLP-1 therapy in our index patient and two other participants
with obesity and type 2 diabetes. We have demonstrated the
presence of iNKTcells in psoriasis lesions, associated with a
relative depletion in circulating iNKT cell number, and a
reversal of this ratio following 6 weeks of therapy with a
GLP-1 analogue in the two non-index participants. GLP-1R
was expressed on iNKT cells and modulated cytokine
production in vitro following stimulation with native GLP-1
or the GLP-1 analogue, liraglutide. The GLP-1 analogue did
not inhibit iNKTcell cytotoxicity function.
iNKT cells have been described as the ‘Swiss-Army
knife’ of the immune system [24]. They represent less than
1% of all peripheral blood T cells, but even so are potent
iNKT cells
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Fig. 2 Activation of GLP-1R on iNKT cells results in upregulation of
cAMP and CREB phosphorylation. a Quantification of cAMP. iNKT
cells (1.5×10
6) were seeded in the presence or absence of plate-bound
anti-CD3 (2 μg/ml) and cultured with the GLP-1 analogue (15 μg/ml)
for the indicated times. As a positive control, cells were incubated for
15 min with the cAMP phosphodiesterase inhibitor, 3-isobutyl-1-
methylxanthine (500 mol/l), and then stimulated for another 30 min
with forskolin (30 μmol/l) cAMP. Cell extracts were prepared and
assayed for levels of cAMP.
†p<0.0001. b iNKT cells (2×10
6) were
seeded in the presence or absence of plate-bound anti-CD3 (2 μg/ml)
and cultured with the GLP-1 analogue (15 μg/ml) or lipopolysaccha-
ride (LPS, 100 ng/ml) for the indicated times. Cell lysates were
subjected to SDS-PAGE and analysed by western blotting using anti-
phospho-CREB, anti-CREB and anti-β-actin antibodies
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Fig. 3 GLP-1 modulates iNKT cell cytokines. IFN-γ (a) and IL-4 (b)
production by iNKT cells (1×10
5) after 24 h co-culture at a 1:1 ratio
with CD1d-transfected C1R cells unloaded in the absence or presence
of GLP-1 (150 μg/ml) (n=5). IFN-γ (c) and IL-4 (d) production by
iNKT cells after 24 h co-culture with CD1d-transfected C1R cells
loaded or unloaded with 100 ng/ml of αGalCer in presence of
increasing concentrations of GLP-1 (0–150 μg/ml, n=3). Cytokine
concentrations were measured by ELISA and analysed using Graph-
Pad Prism (n=3). *p<0.05,
†p<0.005,
‡p<0.0001
2750 Diabetologia (2011) 54:2745–2754drivers of innate and acquired immune responses. Follow-
ing activation, iNKT cells are able to rapidly produce large
quantities of IFN-γ, IL-4 and granulocyte-macrophage
colony-stimulating factor, as well as multiple other cyto-
kines and chemokines (e.g. IL-2, IL-10 and TNF-α). In this
way, iNKT cells mediate both anti-inflammatory Th2-type,
regulatory T cell-type and pro-inflammatory Th1-type
immune responses [14].
Previous studies have demonstrated natural killer cells
and NKT cells in psoriasis plaques to be associated with
reduced numbers in the circulation [25, 26]. It is also
known that psoriatic keratinocytes are enriched in CD1d,
the molecule that presents glycolipid antigen to iNKT cells
[27], and that a CD1d reactive T cell line from a patient
with psoriasis induced psoriasis in a mouse model [28]. We
have demonstrated a reduction in psoriatic plaque iNKTcell
number and an increase in circulatory iNKT cell number,
following 6 weeks of GLP-1 analogue therapy. By contrast,
a previous study investigated the stability of iNKT cell
frequency over time and found that healthy donors
displayed constant levels over a period of 10 months [29].
GLP-1 has been shown to inhibit chemokine-induced
migration of human CD4-positive lymphocytes in vitro, a
critical step in vascular atherosclerotic plaque development
[22]. Inhibition of dipeptidyl peptidase-4 enzymatic degra-
dation of GLP-1 prevented recruitment of pro-inflammatory
macrophages into visceral fat in a mouse model of type 2
diabetes [30]. These modulatory effects of GLP-1 on
immune cell subsets may have important implications for
a range of inflammatory and autoimmune conditions.
The established role of GLP-1 is the regulation of
postprandial glucose excursions by stimulating insulin secre-
tion, inhibiting glucagon release and causing a delay in gastric
emptying. However, a growing body of literature has reported
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Fig. 5 The GLP-1 analogue
liraglutide modulates iNKT cell
cytokine production, but not
cytolytic degranulation of iNKT
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10
5) co-cultured at a 1:1 ratio
with CD1d-transfected C1R
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presence of 15 μg/ml of the
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centrations were measured by
ELISA and analysed using
GraphPad Prism (n=3). c Per-
centage of CD107-positive
iNKT cells after culture with
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receptor agonists. Cardiovascular [31–33], neuroprotective
[34–36] and anti-inflammatory [37, 38] effects have been
described, along with potential therapeutic implications for
multiple disease states. GLP-1 therapy has been shown to
delay the onset of diabetes and restore normoglycaemia in
mouse models of type 1 diabetes [39, 40]. The beneficial
effects of GLP-1 in type 1 diabetes are attributed to trophic
and cytoprotective effects on pancreatic beta cells. In addition,
there is evidence for an immunoregulatory role, with reports
of a shift in cytokine production by islet-infiltrating leucocytes
[39] and of modulation of regulatory T cells [21, 41].
The GLP-1R has been demonstrated in murine immune
tissues [20], and on T and B lymphocytes from mice [20,
21] and humans [22]. We have now demonstrated that GLP-
1R is expressed on human iNKT cells. Unlike conventional
T cells, iNKT cells are innate immune cells, capable of
powerful anti-tumour cytotoxicity responses and rapid
cytokine production following direct antigen stimulation.
The balance of pro- and anti-inflammatory cytokines
produced influences the inflammatory environment and
the subsequent adaptive immune response.
The GLP-1R on iNKT cells is functional and signals in
response to GLP-1. This conclusion is based on the ability
of GLP-1 to promote increased levels of cAMP and induce
phosphorylation of the downstream transcription factor
CREB. These are typical responses of receptors like GLP-
1R, which signals via the Gs protein to activate adenylate
cyclase and increase levels of cAMP. Kim et al. reported
that treatment of mice with a dipeptidyl peptidase-IV (DPP-
IV) inhibitor resulted in an increase in cAMP levels, but the
same was not observed with GLP-1 treatment [23]. We have
now demonstrated that activation of GLP-1R on iNKT cells
results in a significant increase in cAMP levels. The
difference in findings may be explained by our use of a
DPP-IV-resistant GLP-1 analogue. Native GLP-1 is rapidly
degraded by DPP-IV in the circulation and has a half-life of
less than 1 to 2 min [42], whereas liraglutide, a GLP-1
analogue, has a half-life of 13 h [43]. It is also of interest
that GLP-1 promotes activation of the transcription factor
CREB. The latter is known to regulate expression of anti-
inflammatory genes such as IL10 [44], and it is intriguing to
speculate that some of the therapeutic effects of liraglutide
observed in the present study in psoriatic patients may be
related to CREB-induced production of anti-inflammatory
proteins. This is worthy of future investigation.
The addition of native GLP-1 or the GLP-1 analogue to
the iNKT cell co-cultures in vitro resulted in modulation of
biological activity, altering production of the cytokines IFN-
γ and IL-4. GLP-1 modified the cytokine production but
not the cytolytic activity of activated iNKT cells. We
suggest that GLP-1 is immunoregulatory as opposed to
immunosuppressive. The ability of GLP-1 to prime and
inhibit iNKT cell cytokine production supports previous
work indicating an immune cell regulatory role for this
hormone [20–23, 39]. The GLP-1R antagonist exendin 9-
39 was shown to block the modulation of iNKT cell
cytokine production by GLP-1. This confirms that the
modulation observed in iNKT cell cytokine production is
mediated by GLP-1R activation.
The patients in this report had subjective improvement of
psoriasis symptoms within 48 h of starting GLP-1 analogue
therapy, prior to significant weight loss. In addition, the first
patient (index patient) displayed improvement with initial GLP-
1 agonist therapy, deterioration upon withdrawal and rapid
improvement following re-treatment with a GLP-1 analogue. In
a murine model, Hadjiyanni et al. reported that lymphocytes
from Glp1
−/− mice were hyperproliferative in response to
mitogenic stimulation, suggesting that GLP-1 may control
lymphocyte proliferation in mice [21]. Our data suggest that
the rapid clinical improvement observed in these psoriasis
patients may be secondary to direct regulation of iNKT cells
by a GLP-1 analogue. This is supported by alterations in
iNKTcell distribution in vivo and cytokine production in vitro.
Liraglutide therapy was commenced in the two non-
index study participants following the observed improve-
ment in psoriasis in the index patient. Glycaemic control
was excellent at baseline and remained unchanged. Both
non-index participants in the study lost weight after 6 weeks
of therapy. Weight loss has previously been shown to
positively affect circulating immune cell function in mice
[45] and humans [46]. In particular, bariatric surgery-
induced weight loss was shown to reverse impairments in
natural killer cell activity and natural killer cell-related
cytokine synthesis [47]. It is difficult to determine to what
exact extent reduced energy intake or changes in adipose
tissue mass may contribute to the noted changes in iNKT
cell function. However, all patients reported symptom relief
within days of commencing treatment. Expression of the
GLP-1R on the iNKT cell and modulation of cytokine
production in vitro suggest a specific GLP-1-mediated
effect, further supported by the inhibition of these effects
by the GLP-1R antagonist exendin (9-39).
Psoriasis has been shown to improve following Roux-
en-Y gastric bypass (RYGB) surgery [48]. This is thought
to be secondary to substantial weight loss and associated
improvements in metabolic and inflammatory markers.
RYGB also results in an early and sustained increase in
postprandial GLP-1 levels [49]. The in vitro effects of GLP-
1 analogues on iNKT cells demonstrated in the current
study suggest that the improvement in psoriasis following
RYGB may be mediated, at least in part, by the effect of
GLP-1 on iNKT cell cytokine production.
This study focused exclusively on human iNKTcells and
indicates that GLP-1 and GLP-1-based therapies directly
influence human immune function. While the effects seen
2752 Diabetologia (2011) 54:2745–2754in this report are positive in psoriasis, extensive research is
needed to investigate the potential beneficial or adverse
effects of direct GLP-1–immune cell interactions. The
observation that GLP-1 therapy restores circulating iNKT
cell number, directly primes a resting iNKTcell and inhibits
a stimulated iNKT cell further strengthens the link between
the endocrine and human immune system, indicating
potential new therapeutic applications for GLP-1 therapies.
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